Overview
A phthalic indicator dye that appears yellow-green in normal tear film and bright green in a more alkaline medium, such as the aqueous humor, and is used therapeutically as a diagnostic aid in corneal injuries and corneal trauma. It has been approved by FDA for use in externally applied drugs and cosmetics. (From Merck Index, 12th ed; American Medical Association Drug Evaluations; 1995, p2275)
Indication
For diagnostic imaging. Primarily indicated in diagnostic fluorescein angiography or angioscopy of the fundus and of the iris vasculature.
Associated Conditions
- Peritoneal dialysis therapy
- Pneumocystis Jirovecii Pneumonia
Research Report
Fluorescein: A Comprehensive Monograph on its Chemistry, Pharmacology, and Evolving Clinical Utility
1.0 Executive Summary
Fluorescein is a synthetic organic xanthene dye that functions as a highly conspicuous fluorophore, a property that has established it as an indispensable diagnostic agent in medicine for over a century. Identified by DrugBank ID DB00693 and CAS Number 2321-07-5, this small molecule is most renowned for its central role in ophthalmology. Administered intravenously as its water-soluble sodium salt, it is the cornerstone of fluorescein angiography, a procedure critical for visualizing the retinal and choroidal vasculature to diagnose and manage a wide spectrum of disorders, including diabetic retinopathy and age-related macular degeneration. In its water-insoluble free acid form, it is applied topically via ophthalmic strips to detect defects in the corneal epithelium, such as abrasions and ulcers. The fundamental mechanism of action is physical rather than pharmacological; it absorbs blue light and emits a brilliant yellowish-green fluorescence, acting as a passive tracer within biological systems. Its pharmacokinetic profile is characterized by rapid distribution, extensive and swift hepatic metabolism to a fluorescent monoglucuronide metabolite, and primary elimination through renal excretion. While generally considered safe, Fluorescein carries a well-defined risk of adverse reactions, ranging from common, mild effects like nausea to rare but life-threatening hypersensitivity events that necessitate universal precautions during intravenous administration. Beyond its traditional ophthalmic applications, Fluorescein is experiencing a renaissance, with its utility expanding into fluorescence-guided surgery for tumor resection, oncology, and forensic science, demonstrating how technological advancements can unlock new potential in a long-established compound.
2.0 Identification and Physicochemical Properties
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2025/03/13 | Phase 2 | Recruiting | |||
2023/09/26 | Phase 2 | ENROLLING_BY_INVITATION | |||
2022/12/23 | Phase 4 | Completed | |||
2020/04/17 | Phase 2 | Completed | |||
2019/08/28 | Phase 1 | Completed | UpTru Inc. | ||
2019/07/12 | Phase 2 | Active, not recruiting | Aditya Kaza | ||
2019/01/30 | Not Applicable | Recruiting | |||
2018/11/23 | Not Applicable | Terminated | |||
2017/09/29 | Early Phase 1 | Completed | |||
2017/08/10 | Phase 4 | Suspended |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Bausch & Lomb Incorporated | 24208-734 | OPHTHALMIC | 2.6 mg in 1 mL | 8/31/2022 | |
A-S Medication Solutions | 50090-4535 | INTRAVENOUS | 100 mg in 1 mL | 8/15/2016 | |
Altaire Pharmaceuticals Inc. | 59390-205 | OPHTHALMIC | 2.5 mg in 1 mL | 11/1/2022 | |
Akorn | 17478-403 | OPHTHALMIC | 0.6 mg in 1 1 | 3/22/2012 | |
Oceanside Pharmaceuticals | 68682-732 | OPHTHALMIC | 2.6 mg in 1 mL | 3/19/2020 | |
Akorn | 17478-253 | INTRAVENOUS | 100 mg in 1 mL | 8/15/2016 | |
Akorn | 17478-404 | OPHTHALMIC | 1 mg in 1 1 | 3/22/2012 | |
Nexus Pharmaceuticals LLC | 14789-123 | INTRAVENOUS | 250 mg in 1 mL | 10/25/2023 | |
Bausch & Lomb Americas Inc. | 82260-734 | OPHTHALMIC | 2.6 mg in 1 mL | 3/16/2023 | |
HF Acquisition Co LLC, DBA HealthFirst | 51662-1533 | INTRAVENOUS | 100 mg in 1 mL | 8/8/2021 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
RETINOFLUOR fluorescein sodium 10% injection 500mg/5mL vial | 121873 | Medicine | A | 10/22/2007 | |
FLUORESCEIN SERB fluorescein sodium 500mg/5mL injection solution ampoule | 124565 | Medicine | A | 2/13/2007 | |
RETINOFLUOR fluorescein sodium 25% injection | 23138 | Medicine | A | 10/14/1991 | |
Minims Fluorescein Sodium 2% 20mg/mL Eye Drops tube | 32268 | Medicine | A | 10/30/1991 | |
MINIMS lidocaine hydrochloride monohydrate 4% and fluorescein sodium 0.25% eye drops tube | 32272 | Medicine | A | 10/30/1991 | |
MINIMS FLUORESCEIN SODIUM 1% 10mg/mL eye drops tube | 32228 | Medicine | A | 10/30/1991 | |
FLUORESCITE fluorescein 10% 500mg/5mL (as sodium) injection vial | 124267 | Medicine | A | 4/12/2006 | |
RETINOFLUOR fluorescein sodium 10% injection 1g/10mL vial | 23130 | Medicine | A | 10/14/1991 |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
FLUORETS (FLUORESCEIN OPHTHALMIC STRIPS) | dioptic pharmaceuticals inc | 02026252 | Strip - Ophthalmic | 1 MG | 12/31/1994 |
FLUORESCEIN | pharma stulln inc. | 02027097 | Solution - Intravenous | 250 MG / ML | 12/31/1994 |
ODAN-FLUORESCEIN | odan laboratories ltd | 00622869 | Solution - Intravenous | 100 MG / ML | 12/31/1984 |
ODAN-FLUORESCEIN | odan laboratories ltd | 00622877 | Liquid - Intravenous | 250 MG / ML | 12/31/1985 |
MINIMS FLUORESCEIN SODIUM | bausch & lomb inc | 02148390 | Drops - Ophthalmic | 2 % / W/V | 12/31/1995 |
BIO GLO | white ophthalmic services & supply co ltd | 02317281 | Strip - Ophthalmic | 1 MG | 1/28/2009 |
FLUORESCEIN | pharma stulln inc. | 02027089 | Solution - Intravenous | 100 MG / ML | 12/31/1994 |
ODAN-FLUORETS | odan laboratories ltd | 00687812 | Strip - Ophthalmic | 1 MG | 12/31/1986 |
FLUORETS - STP OPH 1MG | chauvin pharmaceuticals limited | 02179539 | Strip - Ophthalmic | 1 MG | 11/1/1996 |
FLUOROX | white ophthalmic services & supply co ltd | 02354993 | Solution - Ophthalmic | 0.25 % | 11/28/2011 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.